Advertisement
Advertisement
U.S. Markets open in 6 hrs 5 mins
Advertisement
Advertisement
Advertisement
Advertisement

Arvinas, Inc. (ARVN)

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
Add to watchlist
54.46-0.08 (-0.15%)
At close: 04:00PM EDT
54.46 0.00 (0.00%)
After hours: 04:30PM EDT
Advertisement
Full screen
Loading interactive chart...
  • Zacks

    Arvinas, Inc. (ARVN) Reports Q2 Loss, Tops Revenue Estimates

    Arvinas, Inc. (ARVN) delivered earnings and revenue surprises of -29.41% and 30.45%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

  • GlobeNewswire

    Arvinas Reports Second Quarter 2022 Financial Results and Provides Corporate Update

    NEW HAVEN, Conn., Aug. 04, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today reported financial results for the second quarter ended June 30, 2022 and provided a corporate update. “This is an exciting time at Arvinas as we remain on track to initiate two pivotal programs with ARV-471 in metastatic breast cancer in the second half of this year, have a clear development pathway fo

  • GlobeNewswire

    Arvinas Appoints John Northcott as Chief Commercial Officer

    NEW HAVEN, Conn., Aug. 01, 2022 (GLOBE NEWSWIRE) -- Arvinas, Inc. (Nasdaq: ARVN), a clinical-stage biotechnology company creating a new class of drugs based on targeted protein degradation, today announced that John Northcott has joined the company in a newly created position of Chief Commercial Officer (CCO). “John is an excellent addition to the Arvinas leadership team, and I am confident that his experience and impressive product development and commercialization track record will play an imp

Advertisement
Advertisement